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Exome screening to identify loss-of-
function mutations in the rhesus macaque
for development of preclinical models of
human disease
Adam S. Cornish, Robert M. Gibbs and Robert B. Norgren Jr.*
Abstract
Background: Exome sequencing has been utilized to identify genetic variants associated with disease in humans.
Identification of loss-of-function mutations with exome sequencing in rhesus macaques (Macaca mulatta) could lead to
valuable animal models of genetic disease. Attempts have been made to identify variants in rhesus macaques by aligning
exome data against the rheMac2 draft genome. However, such efforts have been impaired due to the incompleteness
and annotation errors associated with rheMac2. We wished to determine whether aligning exome reads against our new,
improved rhesus genome, MacaM, could be used to identify high impact, loss-of-function mutations in rhesus macaques
that would be relevant to human disease.
Results: We compared alignments of exome reads from four rhesus macaques, the reference animal and three unrelated
animals, against rheMac2 and MacaM. Substantially more reads aligned against MacaM than rheMac2. We followed the
Broad Institute’s Best Practice guidelines for variant discovery which utilizes the Genome Analysis Toolkit to identify high
impact mutations. When rheMac2 was used as the reference genome, a large number of apparent false positives were
identified. When MacaM was used as the reference genome, the number of false positives was greatly reduced. After
examining the variant analyses conducted with MacaM as reference genome, we identified two putative loss-of-function
mutations, in the heterozygous state, in genes related to human health. Sanger sequencing confirmed the presence of
these mutations. We followed the transmission of one of these mutations (in the butyrylthiocholine gene) through three
generations of rhesus macaques. Further, we demonstrated a functional decrease in butyrylthiocholinesterase activity
similar to that observed in human heterozygotes with loss-of-function mutations in the same gene.
Conclusions: The new MacaM genome can be effectively utilized to identify loss-of-function mutations in rhesus
macaques without generating a high level of false positives. In some cases, heterozygotes may be immediately useful as
models of human disease. For diseases where homozygous mutants are needed, directed breeding of loss-of-function
heterozygous animals could be used to create rhesus macaque models of human genetic disease. The approach we
describe here could be applied to other mammals, but only if their genomes have been improved beyond draft status.
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Background
The study of genetic variants associated with disease is
revolutionizing biomedical research and promises to
make profound changes in clinical practice [1–4]. One
limitation to current approaches has been the high
cost of genome sequencing. However, next generation
sequencing (NGS), which can focus on the “exome”
(the sequences contained in exons), offers a less expen-
sive method. Already, exome sequencing has been used
with great success to identify genomic sequence variants
associated with disease in humans [2, 4–6].
Identifying a genetic variant associated with a human
disease is an important first step, but animal models that
match human phenotypes are necessary to develop effect-
ive therapeutics. Although mouse models have been help-
ful in understanding basic biology, their great evolutionary
distance and biological differences from humans can limit
their utility for preclinical studies [7]. Approximately 90 %
of therapeutic drug candidates fail to advance during the
clinical phases of pharmaceutical development [8]. The
lack of good animal models for efficacy testing is likely
one cause of this high failure rate.
Rhesus macaques (Macaca mulatta) and other nonhu-
man primates are similar to humans in both physiology
and anatomy due to their close evolutionary relationship
[9]. They have proven essential as models for infectious
diseases such as AIDS/HIV and neurological and repro-
ductive disorders [10–16].
Rhesus macaques with genetic variations similar to
those that cause disease in humans might prove invalu-
able as preclinical models. A rhesus macaque model of
Huntington’s disease has been created by inserting a
Huntingtin gene with a pathological number of repeats
into the genome of oocytes using lentiviral vectors [17].
This gain-of-function mutation has been shown to result
in a phenotype similar to human Huntington’s patients
[18]. Recently, the CRISPR/Cas9 system has been used to
genetically modify the genome of a cynomolgus macaque
(Macaca fascicularis) [19]. Although these approaches
have much promise, they require advanced in vitro
fertilization facilities which are very limited for nonhuman
primates.
Another potential approach to providing rhesus ma-
caques models of genetic disease would be to examine the
exomes of “normal” rhesus macaques for high impact
mutations. Each individual human has, on average, three
to five recessive mutations in genes related to Mendelian
disorders. This statistic was first obtained from studies of
consanguineous marriages [20] and later confirmed with
exome analyses [1]. A study that compared SNPs in the
hippocampal RNA sequences of humans and rhesus ma-
caques found that the number of damaging coding varia-
tions was similar in the two species [21]. Assuming a
similar incidence of loss-of-function (LOF) mutations in
rhesus macaques as is found in humans, exome sequen-
cing and analyses could be used to create a catalog of mu-
tations in genes related to Mendelian disorders in large
numbers of animals. Heterozygotes may be immediately
useful. However, if homozygous individuals are required,
heterozygotes with LOF mutations could be bred together
to produce null mutant offspring [9].
Exome analysis requires two important resources: ex-
ome capture probes that can capture genomic fragments
containing exons and a high quality reference genome
against which sequences can be aligned. For humans
and mice, these resources exist. For rhesus macaques,
no species-specific exome capture probe sets are avail-
able. Fortunately, two previous studies have shown that
human probes can be used to capture about 96 % of the
rhesus macaque coding exons with a minimum of 1X
coverage [22, 23]. However, until recently, investigators in-
terested in performing exome analyses in rhesus macaques
were limited to using a draft rhesus genome, rheMac2,
which contained many errors and was incomplete [24].
Serious issues related to using this genome for exome ana-
lyses have been reported [23]. We have recently completed
a high quality reference genome for the rhesus macaque,
MacaM [25]. Here, we show that alignments of exome se-
quences with MacaM can be analyzed to identify LOF mu-
tations in rhesus macaques related to human disease.
Methods
We used two human exome capture kits to enrich for
exons in four rhesus macaques: the TruSeq Exome
Enrichment Kit (Illumina) for animal 002 T-NHP and
the SureSelect XT HumanAllExon 50 Mb Kit (Agilent,
G7544A) for animals 17573, ON12033 and ON22186.
We sequenced exomic fragments with an Illumina Gen-
ome Analyzer IIx (for animal 002 T-NHP) and a HiSeq2000
(for animals 17573, ON12033 and ON22186) and obtained
101 bp paired-end reads for each exome generating a total
of 17.7 Gb of data. We deposited sequences in the Se-
quence Read Archive at the National Center for Biotech-
nology Information (NCBI) under accessions SRX144674
(002 T-NHP), SRX115899 (animal 17573), SRX144808
(animal ON12033) and SRX145282 (animal ON22186).
We followed The Broad Institute’s Best Practices guide-
lines for discovering putative variants utilizing the Gen-
ome Analysis Toolkit (GATK) [26] to identify LOF
mutations. Briefly, we aligned exomic sequences from the
four rhesus macaques to the two different reference rhe-
sus assemblies to be analyzed: rheMac2 (downloaded from
the UCSC Genome Browser on June 24, 2014) and
MacaM (version 7) using bwa mem (version 0.7.5a-r405).
Preliminary analyses indicated that aligning exome reads
against only chromosome files resulted in apparent mis-
alignments of pseudogene reads against coding genes.
When unplaced and unlocalized scaffolds were included
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in the reference assembly, misalignments involving
coding genes were reduced. All data reported in the
results for both rheMac2 and MacaM were collected
using the latter approach. We processed the 8 align-
ment files (four samples x two genomes) to remove PCR
duplicates (using Picard Tools version 1.137), realign
around putative indels (using GATK version 3.4), and re-
calibrate quality base scores (using GATK version 3.4).
We used the Samtools (version 0.1.18) flagstat tool to ob-
tain the “percent aligned” for each of these datasets
(Table 1).
We identified putative variants in the processed align-
ment files with the GATK HaplotypeCaller (version 3.4).
We removed low quality variants using The Broad
Institute’s recommended filters [27]. For SNPs, we removed
variants that had a Depth (DP) < 5, QualByDepth (QD)
score < 2.0, FisherStrand (FS) score > 60.0, RMSMapping-
Quality (MQ) < 40.0, MappingQualityRankSum Test
(MQRankSum) score < −12.5, or a ReadPosRankSumTest
(ReadPosRankSum) score < −8.0. For insertions and dele-
tions, we removed variants that had a DP < 5, QD< 2.0,
FS > 200.0, or ReadPosRankSum < −20.0. We used snpEff
(version 3.1 h) [28] to generate a tab-delimited file with
variant information to identify putative LOF mutations in
both genomes. We obtained the rheMac2 annotation files
from the NCBI ftp genome database on July 20, 2015. For
MacaM, we used annotation version 7.6 [25]. We focused
on mutations expected to cause complete LOF of protein,
specifically premature stop codon and frameshift muta-
tions. We used the Online Mendelian Inheritance in Man
database [29] to select genes known to be involved in dis-
ease in humans. We manually inspected candidate muta-
tions in these genes with the Integrated Genome Viewer
(IGV) [30]. We did not further investigate variants that did
not seem likely to result in a high impact mutation. Coding
variant statistics were obtained using SnpEff following
filtering and annotation.
We designed PCR primers with Primer3 [31] to flank
target exons containing candidate mutations in two
genes, butyrylcholinesterase (BChE) and ribonuclease L
(RNASEL). We included M13F (−20) sequence (GTAA
AACGACGGCCAGT) and M13R sequence (GGAAA-
CAGCTATGACCATG) on the 5' end of the primer se-
quences to facilitate Sanger sequencing.
Primer sequences:
BChE (forward):
GTAAAACGACGGCCAGTGGGGACAACAAATGC
TTCAT
BChE (reverse):
GGAAACAGCTATGACCATGTGGAACCCAAACAC
TGACCT
RNASEL (forward):
GTAAAACGACGGCCAGTGGGCCATATACTGCCT
TGAA
RNASEL (reverse):
GGAAACAGCTATGACCATGATTCTGCATGATGG
GAGAGG
Integrated DNA Technologies (Coralville, Iowa) syn-
thesized the primers. We performed PCR with these
primers and genomic DNA from two animals from the
Oregon National Primate Research Center, ON12033
(RNASEL) and ON22186 (BChE). Briefly, 200 ng of gen-
omic DNA was used as the template for PCR using the
AccuPrime Pfx Supermix Kit (Invitrogen) according to
the manufacturer’s instructions. We amplified targeted
exons in a MJ Research PTC-100 thermocycler with the
following program:
Step 1. Denature at 95 °C for 5 minutes.
Step 2. For 35 cycles: 95 °C for 15 seconds; 60 °C for
30 seconds; 68 °C for 45 seconds.
We purified PCR products with the QIAquick PCR
Purification Kit (Qiagen) and then sequenced the PCR
products with the Sanger method. We manually inspected
traces to identify putative mutations.
We performed PCR for BChE on genomic DNA from
descendants of ON22186 including: ON22187, ON22188,
ON22191, ON22192 and ON22193.
To determine whether an identified LOF mutation in the
BChE gene (in the heterozygous state) resulted in a de-
crease in BChE activity, a functional assay for this enzyme
was performed. 4 ml of heparinized whole blood was drawn
from two animals at the Oregon National Primate Research
Center. One animal, ON22193, had been identified with a
LOF mutation (in the heterozygous state) in the BChE
Table 1 Percent of rhesus exome reads aligned against different assemblies
Sample ID Sample accession rheMac2
assembly
chr only
MacaMv7
assembly
chr only
rheMac2
assembly
chr + unplaced
MacaMv7
assembly
chr + unplaced
17573 SRX115899 94.28 % 97.03 % 96.74 % 97.57 %
ON12033 SRX144808 93.19 % 96.29 % 95.98 % 96.95 %
ON22186 SRX145282 92.62 % 96.21 % 95.84 % 96.95 %
002T-NHP SRX144674 92.09 % 95.12 % 94.87 % 95.84 %
Chr only alignments against only scaffolds placed on chromosomes; Chr + unplaced alignments against both placed and unplaced scaffolds
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gene. Animal ON22197 was an unrelated cage mate. Both
animals were female.
The whole blood was transferred to sterile microfuge
tubes using aseptic conditions. 0.4 ml was placed in a
nonsterile tube for activity assays. Tubes were centri-
fuged for 10 min to pellet the red blood cells. The red
blood plasma was then transferred to new tubes.
BChE activity was measured in 0.1 M potassium phos-
phate buffer pH 7.0 containing 0.5 mM dithiobisnitro-
benzoic acid, and 1 mM butyrylthiocholine at 25 °C. The
increase in absorbance was recorded at 412 nm and con-
verted to μmoles butyrylthiocholine hydrolyzed per min
using the extinction coefficient 13,600 M−1 cm−1 [32].
Units of activity were measured in μmoles per minute.
Each plasma sample was assayed in triplicate.
Two specific BChE inhibitors, 20 μM ethopropazine,
and 0.1 mM iso-OMPA were used to demonstrate that
the measured activity was catalyzed by BChE. Plasma
was preincubated with 0.1 mM iso-OMPA for 30 minutes
before the reaction was started by addition of 0.02 ml of
0.2 M butyrylthiocholine.
Statement of ethical approval
Materials used in these studies were from animal work
performed under Institutional Animal Care and Use
Committee approval from the University of Nebraska
Medical Center and Oregon Health and Sciences Uni-
versity. Animal welfare was maintained by following
NIH (Public Health Service, Office of Laboratory Animal
Welfare) and USDA guidelines by trained veterinary staff
and researchers under Association for Assessment and
Accreditation of Laboratory Animal Care certification,
insuring standards for housing, health care, nutrition,
environmental enrichment and psychological well-being.
These met or exceeded those set forth in the Guide for
the Care and Use of Laboratory Animals from the Na-
tional Research Council of the US National Academy of
Sciences.
Results
We aligned exome capture reads from four rhesus ma-
caques against rheMac2 and MacaM (Table 1). Substan-
tially more reads aligned against MacaM than rheMac2
when reads were aligned only against scaffolds placed on
chromosomes. When unplaced scaffolds were used, the
differences in alignment percentages between rheMac2
and MacaM were greatly reduced.
We used GATK HaplotypeCaller to identify potentially
high impact mutations in the four rhesus macaque
exomes using the rheMac2 and MacaM assemblies
(Table 2). Substantially more LOF mutations were called
when exome sequences were aligned against rheMac2 than
MacaM. One way to determine whether these calls are
accurate is to examine putative homozygous mutations
identified in the reference animal, 17573. Since sequences
from 17573 were used to create both the rheMac2 and
MacaM assemblies, no homozygous mutations should be
called when exome sequences from this animal are aligned
against the reference assemblies.
In general, our results suggest a high false positive rate
when rheMac2 is used as the reference genome. For
example, with rheMac2, 610 homozygous frameshifts
were called in animal 17573 compared to 350 heterozy-
gous frameshifts (Table 2). This pattern of mutation is
extremely unlikely from a biological perspective. When
we used MacaM as the reference genome, we observed
92 heterozygous and 4 homozygous frameshifts, sug-
gesting a much lower false positive rate with this rhesus
macaque genome. A similar pattern of higher false pos-
itives with the rheMac2 genome than with the MacaM
Table 2 Variant calls for exomes aligned against rheMac2 and
MacaM7 assemblies
rheMac2 rheMac2 MacaM7 MacaM7
Variant Het Hom Het Hom
Animal 17573
START_LOST 34 4 8 0
STOP_GAINED 200 25 42 0
STOP_LOST 86 70 5 0
FRAME_SHIFT 394 669 100 4
SPLICE_SITE_ACCEPTOR 59 49 27 0
SPLICE_SITE_DONOR 70 38 28 3
Animal ON12033
START_LOST 36 19 13 4
STOP_GAINED 278 84 99 9
STOP_LOST 71 132 6 3
FRAME_SHIFT 618 722 232 29
SPLICE_SITE_ACCEPTOR 74 68 45 11
SPLICE_SITE_DONOR 91 71 50 13
Animal ON22186
START_LOST 29 20 9 4
STOP_GAINED 211 77 59 6
STOP_LOST 68 116 10 0
FRAME_SHIFT 484 778 188 24
SPLICE_SITE_ACCEPTOR 69 64 33 14
SPLICE_SITE_DONOR 73 60 34 13
Animal 002 T-NHP
START_LOST 25 18 10 2
STOP_GAINED 222 67 86 5
STOP_LOST 55 112 10 1
FRAME_SHIFT 505 654 228 27
SPLICE_SITE_ACCEPTOR 77 57 52 6
SPLICE_SITE_DONOR 84 60 48 10
Cornish et al. BMC Genomics  (2016) 17:170 Page 4 of 11
genome was also observed for other types of mutations
(Table 2).
Although there were many fewer false positives with
MacaM than rheMac2, it was still necessary to filter the
output from SnpEff to focus on the candidate variants
most likely to have a high impact. For example, apparent
variants that were found in multiple, unrelated animals
were considered unlikely to be high impact. We found
that manual inspection of putative high impact muta-
tions in IGV was helpful in understanding why this was
so. In some cases, snpEff reported variants which, when
considered in isolation, would cause high impact muta-
tions, but when considered in context, did not cause a
significant change in the genome. For example, a change
in one nucleotide reported to result in a premature stop
codon in the chloride channel accessory 4 (CLCA4) gene
actually did not cause a premature stop codon because
an adjacent nucleotide change prevented a stop codon
from being produced (Fig. 1a). In another case, a re-
ported disruption of the splice donor site by the inser-
tion of “TA” after the “G” in a splice donor site of the
acetyl-CoA carboxylase alpha (ACACA) gene would in
fact would still result in an intact “GT” (Fig. 1b).
Incorrect alignments also appeared to be responsible
for incorrect calls. In preliminary experiments, we
aligned exome reads against chromosome files alone.
We noted a significant numbers of “high impact” calls in
regions with apparent very high polymorphism and allele
ratios that were far from 1:1. We hypothesized that the
exome capture kits had pulled down pseudogene frag-
ments and that because pseudogenes had not been in-
cluded in our chromosome assembly these fragments
were aligned against coding genes similar in sequence to
pseudogenes thus creating false positive signals. To test
this hypothesis and attempt to decrease false positives,
we redid our analyses, this time including unplaced scaf-
folds in the alignment step. Our reasoning was that
pseudogene exome fragments would now align against
pseudogene loci in the unplaced scaffolds rather than
against protein coding genes thereby reducing the number
of false positives due to misalignments. In fact, we did
observe a dramatic reduction in such false positives after
including unplaced scaffolds for alignments [data not
shown]. We also observed that there were many more ap-
parent false positives due to misalignment in animal
002T-NHP than the other three animals [data not shown].
It may be that the TruSeq Exome Enrichment Kit, which
was used only for this animal, contained probes which
were more likely to hybridize to pseudogene fragments
than the the SureSelect XT HumanAllExon 50 Mb Kit,
which was used for the other three animals.
Exome analysis using MacaM as the reference identi-
fied many variants (Additional file 1: Table S1). As
expected, mutations in noncoding regions were much
Fig. 1 Mutations identified as “high impact” by SnpEff but which likely
have no impact. a. An A > T mutation at position 86408706 of
chromosome 1 (black arrow) was identified as a premature stop codon
by SnpEff. If this mutation had happened in isolation, it would in fact
result in p.Lys374* in the CLCA4 protein (bottom frame), as predicted
by SnpEff. However, because there was also an A > G mutation in the
adjacent nucleotide (blue arrow), the actual change would be
p.Lys374Trp, a missense, not a LOF mutation. b. A “TA” insertion at
position 30707229 of chromosome 17 (black arrow) was identified as a
“high impact” splice_donor_variant by SnpEff. In fact, this insertion
would leave a “GT” donor intact. It would simply replace one “T” for
another. It is also possible that HaplotypeCaller had difficulty with the
alignments in this region due to “TATA” repeats. For both 1A and 1B,
mutations are reported for animal 17573 using the MacaM genome.
Figures are screenshots of alignments viewed with IGV.
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more common than mutations in coding regions
(especially nonsense mutations) (Table 3). As a per-
cent of total SNPs located in the CDS, synonymous SNPs
constituted 64.6 to 65.7 % of the total, non-synonymous
SNPs constituted 34.1 to 35.2 % of the total and nonsense
SNPs constituted 0.2 to 0.3 % of the total (Table 3). We
also examined splice sites for exons containing coding
sequence (CDS) and untranslated regions (UTR)
(Additional file 2: Table S2). Mutations at splice sites
were rare for all exons suggesting that both types of
junctions are under negative selection.
We focused our analysis on two apparent high impact
mutations in genes known to be related to human gen-
etic disease, ribonuclease L (RNASEL) in animal
ON12033 (chr01: 184268143) and BChE in animal
ON22186 (chr03:69751554). Both mutations were anno-
tated as “STOP-GAINED” in the heterozygous state by
SnpEff with high confidence scores. The raw QUAL
scores for these two mutations were 2755.77 and
1186.77, respectively. The mutation in the RNASEL gene
(p.R552X) occurred in the fourth exon. This mutation
was visualized with IGV (Fig. 2a) and validated with
Sanger sequencing (Fig. 2b). The mutation in the
BCHE gene (p.G180X) occurred in the second exon.
This mutation was also visualized with IGV (Fig. 3a)
and validated with Sanger sequencing (Fig. 3b). We
determined the transmission of BCHE in a family of
rhesus macaques using Sanger sequencing of exon 2
(Fig. 4). This mutation was transmitted across three
generations (Fig. 4).
To determine whether the LOF mutation in BChE in the
heterozygous state decreased BChE activity in rhesus ma-
caques as it would in humans, we collected blood from ani-
mal ON22193 (a third generation carrier of the mutation)
and animal ON22197 (an unrelated cage mate). Analysis of
the serum of these two animals revealed that the heterozy-
gous mutant had 30 % of the BChE activity of its unrelated
cage mate (Table 4).
Discussion
We have previously demonstrated that MacaM yields
better results than rheMac2 for mRNA-sequence expres-
sion analysis [25, 33]. We now demonstrate that MacaM
also performs better than rheMac2 for exome analysis.
More exome reads align against the MacaM chromo-
some assembly than the rheMac2 assembly (Table 1).
This gap largely disappears when unplaced scaffolds are
included for the alignments (Table 1) suggesting that
more of the rhesus genome is represented in the MacaM
chromosome assembly than in the rheMac2 chromo-
some assembly. Further, MacaM has many fewer false
positives than rheMac2 (Table 2). Although it is tempting
to aggressively annotate as many genes as possible, for ex-
ome studies the cost of incorrectly annotating genes is
very high. This is because an unacceptable number of false
positive high impact mutations will result from these er-
rors. This is likely in part due to the fact that the Gnomon
automated annotator used by NCBI will use intronic se-
quence when an exon for a gene is missing from the
chromosome assembly [24]. Since introns are often poorly
conserved, attempts to align sequence against spurious
“exons” (actually intronic sequence) will frequently result
in apparent highly damaging mutations. The most time-
intensive step in exome studies is filtering false-positives.
Adding large numbers of false-positives as a result of in-
correct gene annotations has made using the rhesus anno-
tations for rheMac2 for exome studies in rhesus macaques
impractical [23].
The overall number of SNPs and percent nonsense
mutations that we observed for rhesus macaques are
similar to those reported for humans [5]. The relative
number of synonymous to non-synonymous SNPs,
about 2 to 1, that we observed in rhesus macaques was
strikingly similar to the ratio reported by Yuan et al. for
rhesus macaque [21] but different from the approxi-
mately 1 to 1 ratio found in humans [5]. Negative selec-
tion is apparently acting in both species to limit the
number of deleterious mutations.
Our results suggest that the new MacaM genome can
be used with exome data to screen rhesus macaques for
naturally occurring LOF mutations in genes related to
human disease. We describe LOF mutations, in the het-
erozygous state, in two genes related to human health,
RNASEL and BChE.
LOF mutations in RNASEL have been linked to sus-
ceptibility to prostate cancer in humans [34, 35]. Individ-
uals with LOF germline mutations in the heterozygous
state developed prostate tumors with complete loss of
function (loss of heterozygosity) [34, 35]. Rhesus ma-
caque heterozygotes with LOF mutations in the RNA-
SEL gene might serve as important animal models for
prostate cancer.
Table 3 SNPs located in CDS
17573 ON12033 ON22186 002 T-NHP
Synonymous 15,689 (64.6 %) 30,566 (65.7 %) 23,145 (64.9 %) 25,066 (65.0 %)
Non-synonymous 8563 (35.2 %) 15,874 (34.1 %) 12,416 (34.8 %) 13,399 (34.7 %)
Nonsense 50 (0.2 %) 109 (0.2 %) 100 (0.3 %) 99 (0.3 %)
Total 24,302 46,549 35,661 38,564
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Humans with mutations in the BChE gene that de-
crease or eliminate expression of butyrylcholinesterase
have prolonged apnea in response to exposure to suc-
cinylcholine or mivarcurium [36]. Further, treatment
with BChE has been shown to be protective against a
nerve agent, Soman, in rhesus macaques [37] indicat-
ing the possible importance of the levels of this en-
zyme in the likelihood of surviving exposure to nerve
agents. We demonstrated that a rhesus macaque with
a LOF mutation in the BChE gene in the heterozy-
gous state had decreased BChE activity compared to
an unrelated cagemate. Rhesus macaques with LOF
mutations in the BChE gene may serve as useful
models for pharmacogenomics and perhaps in the
evaluation of the effects of nerve agents in individuals
with varying levels of BChE activity.
Rare mutations are more likely to be present in the
heterozygous state. For some diseases, the heterozygous
mutants themselves would be useful. For Mendelian
recessive genetic diseases, heterozygotes could be bred
together to increase the numbers of homozygote null
mutant rhesus macaques. In this way, nonhuman pri-
mate models of LOF human genetic disease could be
produced. Given that there are tens of thousands of ma-
caques at primate centers and at private facilities and
that every animal likely harbors one or more interesting
mutations, models for many genetic diseases could likely
be created with a program of exome screening, genotyp-
ing and directed breeding.
The exome screening and directed breeding approach
suggested here could provide a much-needed alternative
to mouse models of human genetic disease. Given the
Fig. 2 LOF premature stop codon mutation in the RNASEL gene in animal ON12033. a. IGV screenshot of mutation (in the heterozygous state) in
the RNASEL gene in position 184268143 of chromosome 1 (arrow). The top frame is correct. The C > T mutation results in p.Arg552* in animal
ON12033. b. Sanger sequence trace indicating the premature stop codon RNASEL c.1654C > T mutation in the heterozygous state (arrow) in
animal ON12033
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many similarities in physiology and behavior between
monkeys and humans, macaque models of genetic dis-
ease have the potential to transform preclinical research
by providing greatly improved tests of the effectiveness
of therapeutic agents.
Our work also provides motivation to improve other
draft genomes. Other mammalian species, for which
there are currently only draft genomes, could provide
useful animal models for human disease using the ex-
ome screening and directed breeding approach we sug-
gest here; but only if their genomes have been upgraded
to MacaM level quality.
There has been great interest in CRISPR/Cas9 and
other targeted approaches to producing null mutant ani-
mals in species other than mice. The advantage of these
methods is that one can choose whichever target one
wishes. However, they require use of assisted reproduct-
ive technologies (ARTs). For nonhuman primates, there
are relatively few centers that have the necessary equip-
ment and expertise to produce targeted null mutant ani-
mals due to limitations in access to the ARTs. The
advantage of our suggested approach is that exome
sequencing and conventional breeding are within the
reach of most centers.
There are disadvantages to screening for naturally oc-
curring mutations. Some genetic diseases are caused by
rare de novo mutations (gain-of-function or dominant
negative loss-of-function) that are not compatible with
reproduction. In these cases, it would be difficult to pro-
duce a line of animals to study (although the animal
with the de novo mutation could be examined and ex-
ome sequencing of this animal would reveal the molecu-
lar basis of its likely obvious phenotype). For many
Mendelian recessive diseases, homozygous LOF animals
would not be able to reproduce, so maintenance of
unaffected lines of male and female heterozygous LOF
animals would be required to produce new homozy-
gotes. Another disadvantage to our approach is that one
does not know in advance which mutations one will find.
It is likely that each center which houses nonhuman
primates will have its own set of mutations due to
the founder effect and restricted breeding policies.
The more animals and centers that are screened, the
greater the number potential animal models that will
Fig. 3 LOF premature stop codon mutation in the BChE gene. a. IGV screenshot of mutation (in the heterozygous state) in the BChE gene in
position 69751554 of chromosome 3 (arrow). Because the gene is running in the antisense direction, the reference sequence should be read
right to left. The aligned sequences are not reverse complemented so “C” = “G” and “A” = “T” with respect to the reference sequence. The top
frame is correct. The G > T mutation results in p.Gly180*. This figure depicts exome sequence alignments for animal ON22186, the original animal
in which the BChE mutation was detected. b. Sanger sequence trace indicating the premature stop codon BChE c.538G > T mutation in the
heterozygous state (arrow) in animal ON22193, a third generation descendant of animal ON22186
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be identified. In principal, if enough animals are
screened, eventually LOF mutations in every gene re-
lated to disease in humans will be identified.
In the current work, we focused on unequivocal loss-
of-function mutations (stop-gain, frameshifts, etc.).
However, human genetic disease can be caused by
subtler mutations such as substitutions which result
in a change of a single amino acid (pathogenic mis-
sense mutations). Although there are programs for
estimating whether changes in amino acids are “dele-
terious”, they generally require a database of proteins
with defined functional domains and/or a database of
proteins from multiple species. Although attempts to
use programs such as Polyphen-2 [38] to identify
“deleterious” missense mutations in rhesus macaques
have been made [39], these programs were primarily
intended to be used with human data [38]. Such pro-
grams often rely, in part, on search against proteins
derived from other mammals. However, we have re-
ported that the draft rhesus macaque genome, and
likely all other draft genomes, is incomplete or incor-
rect for approximately 50 % of all genes [24]. Hence,
attempts to identify evolutionarily conserved regions within
mammals have been fraught with difficulty. This may be
one reason why the true impact of missense mutations
scored as “deleterious” (are they truly pathogenic?) can be
difficult to predict. As more mammalian genomes are
brought to the same level of quality as the MacaM genome,
databases which include conserved regions among mam-
mals are likely to improve, perhaps leading to predictive
programs which identify “deleterious” mutations that are
truly pathogenic.
In addition to evolutionary conservation, documented
association of a missense mutation with a negative
phenotypic effect and variation among large numbers of
humans is an invaluable source of information for deter-
mining whether or not an amino acid change is likely to
be pathogenic. It is important to note that, due to
species-specific differences in protein function, a variant
which is pathogenic in humans is not necessarily patho-
genic in rhesus macaques or other mammals. However,
examination of large numbers of rhesus macaques for
protein variation will likely be a fruitful strategy to deter-
mine which variants are likely to be pathogenic in this
species.
Conclusions
NGS sequences of rhesus DNA fragments captured with
human exome kits can be can be aligned against the
new MacaM genome and the results analyzed according
to GATK best practices to identify high impact variants.
Identification of heterozygous LOF mutations combined
with directed breeding could be used to create rhesus
macaque models of human genetic disease. This is
potentially an important step in advancing translational
research. This approach could also be applied to other
mammalian species.
Availability of supporting data
The exome sequence data sets supporting the results of this
article are available in the Sequence Read Archive reposi-
tory under accessions SRX144674 [http://www.ncbi.nlm.-
nih.gov/sra/SRX144674], SRX115899 [http://www.ncbi.nl
m.nih.gov/sra/SRX115899], SRX144808 [http://www.ncbi.
nlm.nih.gov/sra/SRX144808] and SRX145282 [http://www.
ncbi.nlm.nih.gov/sra/SRX145282].
Additional files
Additional file 1: Table S1. List of effects of mutations in four rhesus
macaques (17573, ON12033, ON22186 and 002T-NHP) as annotated by
SnpEff. SNV = single nucleotide variant; Indel = insertion or deletion. Effects
are as follows: Intergenic = in the intergenic region. Upstream = upstream
of a gene by at most 5kbp. Downstream = downstream of a gene by at
most 5kbp. 5' UTR = located in the 5' UTR. 3' UTR = located in the 3' UTR.
Intronic = between two exons. Splice Acceptor = two bases before exon
start. Splice Donor = two bases after coding exon’s end. Splice Region = in
the putative (Lariat) branch point, located in the intron. Frameshift = indel in
the coding region that is not a multiple of 3. Inframe indel = indel in the
coding region that is a multiple of 3. Start Lost = start codon is mutated to
Table 4 Butyrlcholinesterase activity (units/ml) in a BChE LOF
heterozygote (ON22193) and wild type cage mate (ON22197)
Animal
ID
BChE activity -
No inhibitor
BChE activity - 20 μM
ethopropazine
BChE activity -
0.1 mM iso-OMPA
ON22193 1.38 0 0
ON22197 4.65 0 0
Fig. 4 BChE transmission across three generations of rhesus
macaques. * indicates that animal ON22193 was used for the BChE
activity assay. This is also the animal whose BChE mutation is
depicted in Fig. 3b.
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non-start codon. Stop gained = non-stop codon is mutated to stop codon.
Stop Lost = stop codon is mutated to non-stop codon. (DOCX 116 kb)
Additional file 2: Table S2. Number of variants at splice sites and
percent of total splice sites for CDS and UTR exons provided for four rhesus
macaques (17573, ON12033, ON22186 and 002T-NHP). (DOCX 11 kb)
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